Effects of PG2 on Fatigue-Related Symptom Clusters

This study is for an "add-on" study to the "main" study (Protocol No.: PH-CP012). The information of patients from main study will be collected by questionnaire survey and actigraphy measurement to evaluate the relationship between fatigue, depression and sleep disorder and the efficacy of PG2 after treatment.The association between symptom cluster and circadian rhythm will be also further explored.

Study Overview

• Status: Completed
• Conditions: Cancer-related Fatigue
• Intervention / Treatment: Drug: Astragalus Polysaccharides 500 mg; Drug: Astragalus Polysaccharides 250 mg

Detailed Description

The study is "PG2 Treatment for Improving Fatigue among Advanced Cancer Patients under Standard Palliative Care" (Protocol Number: PH-CP012) of the additional plan, through questionnaires and using actigraphy measuring circadian rhythm collect patient data master plans, assessed for "PG2" treatment of cancer patients before and after treatment fatigue, depression, sleep disorders and other related symptoms of resistance and the effectiveness of treatment, and to further explore the symptom clusters in cancer patients associated with the circadian rhythm

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Taiwan
  • Taipei, Taiwan, 235
    • Taipei Medical University -Shung Ho Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients who signed the informed consent form
• The age of eligible patients should be 20 years old.
• Eligible patients must have locally advanced or metastatic cancer or inoperable advanced cancer.
• Patients are under standard palliative care (SPC) at hospice setting and have no further curative options available.
• Patients with BFI fatigue score 4 during screening.
• Patients have a life expectancy of at least 3 months as determined by the investigator.
• Patient must be willing and able to complete quality of life questionnaires.

Exclusion Criteria:

• Female patients are pregnant or breast-feeding.
• Patients with uncontrolled systemic disease such as active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus.
• Patients take central nervous system stimulators such as Methylphenidate within 30 days before screening.
• Patients have enrolled or have not yet completed other investigational drug trials within 30 days before screening.
• Patients with Karnofsky Performance Scores less than 30 % at time of screening
• Patients who are diagnosed as dying status

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Astragalus Polysaccharides 500 mg; PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)	Drug: Astragalus Polysaccharides 500 mg; PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks); Other Names: PG2 Injection 500 mg PG2 (500 mg in 500 ml saline)
Experimental: Astragalus Polysaccharides 250 mg; PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)	Drug: Astragalus Polysaccharides 250 mg; PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks); Other Names: PG2 Injection 250 mg PG2 (250 mg in 500 ml saline)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pittsburgh Sleep Quality Scale		about 5-10 minutes
Hospital Anxiety and Depression Scale		about 5-10 minutes
Actigraphy measuring circadian rhythm	three measurements means:3 days prior to the first dose of study medication began wearing courses of the last visits to the first week; last treatment of 3rd and 7th weeks of medication visits began wearing last time between the 4th and 8th week of visits	3-month course of treatment, a total of three measurements, each measurement 7 days

Collaborators and Investigators

• Sponsor: Taipei Medical University
• Investigators: Principal Investigator: Lin C Chin, PhD., RN, Taipei Medical University

Study record dates

Study Major Dates

• Study Start: March 1, 2016
• Primary Completion (Actual): May 8, 2017
• Study Completion (Actual): May 8, 2017

Study Registration Dates

• First Submitted: February 16, 2016
• First Submitted That Met QC Criteria: April 12, 2016
• First Posted (Estimate): April 15, 2016

Study Record Updates

• Last Update Posted (Actual): September 12, 2018
• Last Update Submitted That Met QC Criteria: September 11, 2018
• Last Verified: September 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Syndrome; Fatigue
• Other Study ID Numbers: N201509006

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No